Allygen Biosciences
↗Shanghai, China
Allygen Biosciences is a clinical-stage-ready biotechnology company specializing in the development of next-generation biologics, particularly bispecific antibody-drug conjugates (BiADCs). The company utilizes its proprietary STAR (Smart TME Activated Release) technology to design therapies that are selectively activated within the tumor microenvironment, aiming to enhance efficacy while reducing systemic toxicity.
Headquartered in Shanghai with corporate structures in Hong Kong and the Cayman Islands, Allygen focuses on high-value oncology targets such as PD-L1 and Trop-2. Their lead candidate, ALG01, has demonstrated significant anti-tumor activity and a favorable safety profile in preclinical models, positioning the company as an emerging player in the competitive ADC landscape.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:Pre-revenue
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Series A (estimated)
Investors:Allygen Group (Cayman), Private Venture Capital
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical (IND-enabling)
Modalities:Bispecific Antibody, ADC, BiADC, Oligonucleotide Conjugates
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Allygen Group (Cayman)
Subsidiaries:Allygen Biologics (HK) Limited, Shanghai Lianjin Biotechnology Co., Ltd.
Key Partnerships:AACR (Scientific presentation partner)
COMPETITION
Position:Emerging
Competitors:Gilead Sciences (Trodelvy), AstraZeneca/Daiichi Sankyo (DS-1062), Biotheus/BioNTech, Helixon, Sistimmune
LEADERSHIP
Key Executives:
Wenlong Gao - CEO & Co-founder
Jun Xiang - Co-founder & Chief Scientist
Scientific Founders:Wenlong Gao, Jun Xiang
LINKS
Website:allygenbio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Allygen Biosciences. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.